Literature DB >> 26825008

Quantitation of the Minor Tobacco Alkaloids Nornicotine, Anatabine, and Anabasine in Smokers' Urine by High Throughput Liquid Chromatography-Mass Spectrometry.

Linda B von Weymarn1, Nicole M Thomson1, Eric C Donny2, Dorothy K Hatsukami3, Sharon E Murphy1.   

Abstract

Nicotine is the most abundant alkaloid in tobacco accounting for 95% of the alkaloid content. There are also several minor tobacco alkaloids; among these are nornicotine, anatabine, and anabasine. We developed and applied a 96 well plate-based capillary LC-tandem mass spectrometry method for the analysis of nornicotine, anatabine, and anabasine in urine. The method was validated with regard to accuracy and precision. Anabasine was quantifiable to low levels with a limit of quantitation (LOQ) of 0.2 ng/mL even when nicotine, which is isobaric, is present at concentrations >2500-fold higher than anabasine. This attribute of the method is important since anatabine and anabasine in urine have been proposed as biomarkers of tobacco use for individuals using nicotine replacement therapies. In the present study, we analyzed the three minor tobacco alkaloids in urine from 827 smokers with a wide range of tobacco exposures. Nornicotine (LOQ 0.6 ng/mL) was detected in all samples, and anatabine (LOQ, 0.15 ng/mL) and anabasine were detected in 97.7% of the samples. The median urinary concentrations of nornicotine, anatabine, and anabasine were 98.9, 4.02, and 5.53 ng/mL. Total nicotine equivalents (TNE) were well correlated with anatabine (r(2) = 0.714) and anabasine (r(2) = 0.760). TNE was most highly correlated with nornicotine, which is also a metabolite of nicotine. Urine samples from a subset of subjects (n = 110) were analyzed for the presence of glucuronide conjugates by quantifying any increase in anatabine and anabasine concentrations after β-glucuronidase treatment. The median ratio of the glucuronidated to free anatabine was 0.74 (range, 0.1 to 10.9), and the median ratio of glucuronidated to free anabasine was 0.3 (range, 0.1 to 2.9). To our knowledge, this is the largest population of smokers for whom the urinary concentrations of these three tobacco alkaloids has been reported.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26825008      PMCID: PMC5155587          DOI: 10.1021/acs.chemrestox.5b00521

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  25 in total

1.  Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

Authors:  P Jacob; L Yu; A T Shulgin; N L Benowitz
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

2.  Specific detection of anabasine, nicotine, and nicotine metabolites in urine by liquid chromatography-tandem mass spectrometry.

Authors:  Andrew N Hoofnagle; Thomas J Laha; Petrie M Rainey; Sayed M H Sadrzadeh
Journal:  Am J Clin Pathol       Date:  2006-12       Impact factor: 2.493

3.  Quantitation of nicotine, its metabolites, and other related alkaloids in urine, serum, and plasma using LC-MS-MS.

Authors:  Bingfang Yue; Mark M Kushnir; Francis M Urry; Alan L Rockwood
Journal:  Methods Mol Biol       Date:  2010

4.  Transfer of exogenously applied and endogenous alkaloids and sterols from tobacco to its smoke condensate.

Authors:  D L Davis; L P Bush; C Grunwald; P L Cornelius
Journal:  J Agric Food Chem       Date:  1977 Jul-Aug       Impact factor: 5.279

5.  Nicotiana glauca toxicosis of cattle.

Authors:  K H Plumlee; D M Holstege; P C Blanchard; K M Fiser; F D Galey
Journal:  J Vet Diagn Invest       Date:  1993-07       Impact factor: 1.279

Review 6.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

7.  A high-throughput robotic sample preparation system and HPLC-MS/MS for measuring urinary anatabine, anabasine, nicotine and major nicotine metabolites.

Authors:  Binnian Wei; June Feng; Imran J Rehmani; Sharyn Miller; James E McGuffey; Benjamin C Blount; Lanqing Wang
Journal:  Clin Chim Acta       Date:  2014-06-23       Impact factor: 3.786

8.  Application of GC-MS/MS for the analysis of tobacco alkaloids in cigarette filler and various tobacco species.

Authors:  Joseph G Lisko; Stephen B Stanfill; Bryce W Duncan; Clifford H Watson
Journal:  Anal Chem       Date:  2013-02-27       Impact factor: 6.986

9.  Analysis of [3',3'-d(2)]-nicotine and [3',3'-d(2)]-cotinine by capillary liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Sharon E Murphy; Peter Villalta; Sing-Wei Ho; Linda B von Weymarn
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-06-29       Impact factor: 3.205

10.  Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users.

Authors:  P Jacob; L Yu; G Liang; A T Shulgin; N L Benowitz
Journal:  J Chromatogr       Date:  1993-09-08
View more
  11 in total

1.  Analysis of N'-nitrosonornicotine enantiomers in human urine by chiral stationary phase liquid chromatography-nanoelectrospray ionization-high resolution tandem mass spectrometry.

Authors:  Jing Yang; Steven G Carmella; Stephen S Hecht
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-01-09       Impact factor: 3.205

Review 2.  Biochemical Verification of Tobacco Use and Abstinence: 2019 Update.

Authors:  Neal L Benowitz; John T Bernert; Jonathan Foulds; Stephen S Hecht; Peyton Jacob; Martin J Jarvis; Anne Joseph; Cheryl Oncken; Megan E Piper
Journal:  Nicotine Tob Res       Date:  2020-06-12       Impact factor: 4.244

3.  Effect of financial voucher incentives provided with UK stop smoking services on the cessation of smoking in pregnant women (CPIT III): pragmatic, multicentre, single blinded, phase 3, randomised controlled trial.

Authors:  David Tappin; Lesley Sinclair; Frank Kee; Margaret McFadden; Lyn Robinson-Smith; Alex Mitchell; Ada Keding; Judith Watson; Sinead Watson; Alison Dick; David Torgerson; Catherine Hewitt; Jennifer McKell; Pat Hoddinott; Fiona M Harris; Kathleen A Boyd; Nicola McMeekin; Michael Ussher; Linda Bauld
Journal:  BMJ       Date:  2022-10-19

4.  Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine.

Authors:  Tracy T Smith; Joseph S Koopmeiners; Katelyn M Tessier; Esa M Davis; Cynthia A Conklin; Rachel L Denlinger-Apte; Tonya Lane; Sharon E Murphy; Jennifer W Tidey; Dorothy K Hatsukami; Eric C Donny
Journal:  Am J Prev Med       Date:  2019-10       Impact factor: 5.043

5.  Lipid laden macrophages and electronic cigarettes in healthy adults.

Authors:  Peter G Shields; Min-Ae Song; Jo L Freudenheim; Theodore M Brasky; Joseph P McElroy; Sarah A Reisinger; Daniel Y Weng; Rongqin Ren; Thomas Eissenberg; Mark D Wewers; Konstantin Shilo
Journal:  EBioMedicine       Date:  2020-09-10       Impact factor: 8.143

6.  Application of HPLC-QQQ-MS/MS and New RP-HPLC-DAD System Utilizing the Chaotropic Effect for Determination of Nicotine and Its Major Metabolites Cotinine, and trans-3'-Hydroxycotinine in Human Plasma Samples.

Authors:  Jacek Baj; Wojciech Flieger; Dominika Przygodzka; Grzegorz Buszewicz; Grzegorz Teresiński; Magdalena Pizoń; Ryszard Maciejewski; Jolanta Flieger
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

7.  Nicotine and Anatabine Exposure from Very Low Nicotine Content Cigarettes.

Authors:  Rachel L Denlinger; Tracy T Smith; Sharon E Murphy; Joseph S Koopmeiners; Neal L Benowitz; Dorothy K Hatsukami; Lauren R Pacek; Cirielle Colino; Samantha N Cwalina; Eric C Donny
Journal:  Tob Regul Sci       Date:  2016-04

8.  Dysregulated Metabolites Serve as Novel Biomarkers for Metabolic Diseases Caused by E-Cigarette Vaping and Cigarette Smoking.

Authors:  Qixin Wang; Xiangming Ji; Irfan Rahman
Journal:  Metabolites       Date:  2021-05-29

9.  Detecting participant noncompliance across multiple time points by modeling a longitudinal biomarker.

Authors:  Ross L Peterson; Joseph S Koopmeiners; Tracy T Smith; Sharon E Murphy; Eric C Donny; David M Vock
Journal:  Clin Trials       Date:  2020-09-14       Impact factor: 2.599

10.  Financial Incentives for Preventing Postpartum return to Smoking (FIPPS): study protocol for a three-arm randomised controlled trial.

Authors:  M Ussher; C Best; S Lewis; J McKell; T Coleman; S Cooper; S Orton; L Bauld
Journal:  Trials       Date:  2021-08-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.